Provectus Biopharmaceuticals Inc (PVCT)
0.1943
0.00 (0.00%)
USD |
OTCM |
May 10, 15:57
Provectus Biopharmaceuticals Enterprise Value: 85.08M for May 9, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 09, 2024 | 85.08M |
May 08, 2024 | 82.61M |
May 07, 2024 | 77.91M |
May 06, 2024 | 76.97M |
May 03, 2024 | 83.89M |
May 02, 2024 | 83.15M |
May 01, 2024 | 84.66M |
April 30, 2024 | 85.92M |
April 29, 2024 | 86.38M |
April 26, 2024 | 86.17M |
April 25, 2024 | 85.29M |
April 24, 2024 | 84.29M |
April 23, 2024 | 84.62M |
April 22, 2024 | 84.62M |
April 19, 2024 | 84.62M |
April 18, 2024 | 84.71M |
April 17, 2024 | 82.61M |
April 16, 2024 | 78.37M |
April 15, 2024 | 73.17M |
April 12, 2024 | 73.13M |
April 11, 2024 | 79.21M |
April 10, 2024 | 74.09M |
April 09, 2024 | 70.02M |
April 08, 2024 | 63.55M |
April 05, 2024 | 65.41M |
Date | Value |
---|---|
April 04, 2024 | 67.19M |
April 03, 2024 | 69.98M |
April 02, 2024 | 76.15M |
April 01, 2024 | 82.65M |
March 28, 2024 | 79.61M |
March 27, 2024 | 86.80M |
March 26, 2024 | 85.54M |
March 25, 2024 | 86.80M |
March 22, 2024 | 82.86M |
March 21, 2024 | 85.96M |
March 20, 2024 | 86.76M |
March 19, 2024 | 85.75M |
March 18, 2024 | 86.80M |
March 15, 2024 | 93.88M |
March 14, 2024 | 87.81M |
March 13, 2024 | 89.64M |
March 12, 2024 | 92.51M |
March 11, 2024 | 88.28M |
March 08, 2024 | 86.28M |
March 07, 2024 | 92.34M |
March 06, 2024 | 74.22M |
March 05, 2024 | 73.53M |
March 04, 2024 | 73.67M |
March 01, 2024 | 69.18M |
February 29, 2024 | 65.28M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
19.33M
Minimum
Oct 19 2022
93.88M
Maximum
Mar 15 2024
43.27M
Average
43.92M
Median
Enterprise Value Benchmarks
Insmed Inc | 4.292B |
NeuroMetrix Inc | -9.237M |
Intra-Cellular Therapies Inc | 6.443B |
Rhythm Pharmaceuticals Inc | 2.144B |
Amylyx Pharmaceuticals Inc | -243.93M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -0.6634M |
Total Expenses (Quarterly) | 0.629M |
Earnings Yield | -2.99% |